At its November 2017 meeting, the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) concluded that, in its pure state, cannabidiol (CBD) does not appear to have abuse potential or cause harm. In humans, CBD exhibits no effects indicative of any abuse or dependence potential and is generally well tolerated with a good safety profile.
In January 2017, one of the most comprehensive and rigorous reviews of relevant scientific research published from 1999 to 2017, "Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research", the ad hoc committee from the National Academies of Sciences, Engineering, and Medicine, states that there was supporting research evidence that cannabis or cannabinoids (such as CBD) were effective for the treatment for chronic pain in adults.
In May 25, 2017, The New England Journal of Medicine published "Trial of Cannabidiol (CBD) for Drug-Resistant Seizures in the Dravet Syndrome," which concluded that among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo, and was associated with lower rates of adverse events.
Staci Gruber, director of Marijuana Investigations for Neuroscientific Discovery (MIND) and an associate professor of psychiatry at Harvard Medical School, is currently conducting the first randomized control clinical trial to evaluate the effects of cannabidiol (CBD) for the treatment of anxiety in adults. She states that she believes the evidence is good that in a lab-based situation, CBD decreases social anxiety.
Associate Professor Joseph Wakshlag at the Cornell University's College of Veterinary Medicine conducted the first Pharmacokinetics double blind, placebo-controlled clinical trial on the use of cannabinoids to treat dogs with osteoarthritis and multi- joint pain; it concluded that dogs who took a proprietary hemp oil blend showed significant improvement over dogs that received the placebo.
Cannabidiol (CBD) (a plant derived cannabinoid) has demonstrated preliminary efficacy for a range of physical and mental health care problems.
CBD has attracted significant research interest due to its and anti-inflammatory, anti-oxidative and anti-necrotic protective effects, as well as displaying a favorable safety and tolerability profile in humans, making it a promising candidate in many therapeutic avenues including Chronic Pain, Epilepsy, Insomnia, Multiple Sclerosis, Migraine Headaches, Mood and Anxiety Disorders, Autoimmune Diseases, Cancer, Substance Abuse, Inflammatory Bowel Disease and so forth.
In the United States and all over the world, hundreds of randomized control trials are now being conducted in an ongoing effort to fully understand the healing power of CBD.
With very promising results found in animal and human studies, only time will tell when research will reveal CBD’s full potentiality, and what could be one of Mother Nature’s most prized gifts to all living things.
A large, well-controlled study of refractory pediatric epilepsy documented a beneficial effect of CBD in reducing seizure frequency by more than 50%.
Read MoreCannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments.
Read MoreIn addition to endorphin release, the “runner’s high” experience after exercise has been shown to be induced in part by Anandamide (an endocannabinoid) acting on CB1 receptors, in mice.
Read MoreIn a large 2019 case series, CBD displays promise as a tool for reducing anxiety in clinical populations. Anxiety scores decreased within the first month in 79.2% of the subjects.
Read MoreThe activity of CBD at 5-HT1A receptors may drive its neuroprotective, antidepressive, and anxiolytic benefits.
Read MoreAdministration of CBD via different routes and long-term use of 10 mg/d to 400 mg/d did not create a toxic effect on patients. Doses up to 1500 mg/d have been well tolerated in the literature.
Read MoreIn January 2017, one of the most comprehensive and rigorous reviews of relevant scientific research published from 1999 to 2017, “Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research,” the ad hoc committee from the National Academies of Sciences, Engineering, and Medicine, states that there was research evidence that cannabis or cannabinoids (such as CBD) are therapeutic and effective for the treatment of the following ailments.
In adults with chronic pain, patients who were treated with cannabis or cannabinoids are more likely to experience a clinically significant reduction in pain symptoms
In adults with Multiple Sclerosis (MS) related spasticity, shortterm use of oral cannabinoids improves patient-reported spasticity symptoms.
In adults with chemotherapy induced nausea and vomiting, oral cannabinoids are effective antiemetics.
No orders shall be fulfilled at this time through this website during our pre-launch period. For inquiries, please contact us at info@hempandheroes.com Dismiss